In February 2005, Idun was acquired by Pfizer. Idun Pharmaceuticals creates innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. In addition to its research and development of small molecule activators of apoptosis for cancer therapy, Idun's drug discovery programs are directed to finding small molecule inhibitors of apoptosis for applications in central nervous system disorders, cardiovascular disease, inflammation, and acute organ damage. Idun Pharmaceuticals is a developer of human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. Management believe that control of the cell death process will have utility in treating cancer, neurodegenerative diseases, ischemic disorders, and cardiovascular disease.
